Armata Pharmaceuticals, Inc. SEC filings ARMP
Armata Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jan 27, 2004. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 11, 2026 |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 12, 2025 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 12, 2024 |
| DEFA14A | Additional proxy material | Aug 3, 2023 | — |
| DEF 14A | Proxy statement | Aug 3, 2023 | Sep 14, 2023 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2023 | Sep 14, 2023 |
| DEF 14A | Proxy statement | Oct 17, 2022 | Nov 16, 2022 |
| DEF 14A | Proxy statement | Mar 9, 2022 | Mar 30, 2022 |
| PRE 14A | Preliminary proxy statement | Feb 24, 2022 | Mar 30, 2022 |
| DEFA14A | Additional proxy material | Apr 22, 2021 | — |
| DEF 14A | Proxy statement | Apr 21, 2021 | Jun 7, 2021 |
| DEF 14A | Proxy statement | Feb 26, 2021 | Mar 16, 2021 |
| PRE 14A | Preliminary proxy statement | Feb 9, 2021 | Feb 9, 2021 |
| DEFA14A | Additional proxy material | Oct 22, 2020 | — |
| DEF 14A | Proxy statement | Oct 22, 2020 | Dec 8, 2020 |
| DEFA14A | Additional proxy material | Mar 6, 2020 | — |
| DEF 14A | Proxy statement | Mar 6, 2020 | Mar 26, 2020 |
| PRE 14A | Preliminary proxy statement | Feb 21, 2020 | Feb 21, 2020 |
| DEFA14A | Additional proxy material | Oct 22, 2019 | — |
| DEF 14A | Proxy statement | Oct 22, 2019 | Dec 10, 2019 |
| PRE 14A | Preliminary proxy statement | Oct 11, 2019 | Dec 10, 2019 |
| DEFA14A | Additional proxy material | May 1, 2019 | — |
| DEFA14A | Additional proxy material | Apr 15, 2019 | — |
| DEFM14A | Filing | Apr 4, 2019 | — |
| PREM14A | Preliminary proxy statement | Mar 25, 2019 | May 8, 2019 |
| DEFA14A | Additional proxy material | Jan 14, 2019 | — |
| DEFA14A | Additional proxy material | Jan 4, 2019 | — |
| DEF 14A | Proxy statement | Nov 9, 2018 | Dec 17, 2018 |
| PRE 14A | Preliminary proxy statement | Oct 26, 2018 | Dec 17, 2018 |
| DEF 14A | Proxy statement | Jul 24, 2017 | Sep 7, 2017 |
| PRE 14A | Preliminary proxy statement | Jul 14, 2017 | Jul 14, 2017 |
| DEF 14A | Proxy statement | May 20, 2016 | Jun 20, 2016 |
| PRE 14A | Preliminary proxy statement | May 9, 2016 | May 9, 2016 |
| DEF 14A | Proxy statement | Jul 10, 2015 | Aug 3, 2015 |
| PRE 14A | Preliminary proxy statement | May 15, 2015 | May 15, 2015 |
| DEF 14A | Proxy statement | Nov 25, 2014 | Dec 19, 2014 |
| PRE 14A | Preliminary proxy statement | Nov 7, 2014 | Nov 7, 2014 |
| DEFA14A | Additional proxy material | May 30, 2014 | — |
| DEF 14A | Proxy statement | Apr 30, 2014 | Jun 27, 2014 |
| DEF 14A | Proxy statement | Apr 6, 2009 | May 14, 2009 |
| PRE 14A | Preliminary proxy statement | Mar 23, 2009 | May 14, 2009 |
| DEF 14A | Proxy statement | Mar 28, 2008 | May 15, 2008 |
| DEFA14A | Additional proxy material | Dec 27, 2007 | — |
| DEF 14A | Proxy statement | Nov 21, 2007 | Jan 11, 2008 |
| PRE 14A | Preliminary proxy statement | Nov 6, 2007 | Nov 6, 2007 |
| DEF 14A | Proxy statement | Apr 2, 2007 | May 17, 2007 |
| PRE 14A | Preliminary proxy statement | Mar 19, 2007 | Mar 17, 2007 |
| DEF 14A | Proxy statement | Mar 29, 2006 | May 8, 2006 |
| PRE 14A | Preliminary proxy statement | Mar 17, 2006 | May 8, 2006 |
| DEF 14A | Proxy statement | Apr 14, 2005 | May 26, 2005 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2005 | May 26, 2005 |
| DEF 14A | Proxy statement | Mar 24, 2004 | May 20, 2004 |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ARMP (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- WA
- Headquarters
- Los Angeles, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 921114
- Former names
- AmpliPhi Biosciences Corp (until May 8, 2019); TARGETED GENETICS CORP /WA/ (until Feb 11, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.